BPC-157 vs TB-500

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicBPC-157TB-500
What it is

A 15-amino-acid peptide. FDA describes it as a fragment of a protein originally isolated from human gastric juice.1

A synthetic, N-acetylated peptide matching amino acids 17 to 23 (LKKTETQ) of thymosin beta-4. FDA’s substance registry notes that its identity record does not imply regulatory review or approval.2,3

FDA status

Not FDA-approved

Not an FDA-approved drug1

Not FDA-approved. FDA staff recommended in May 2026 against adding it to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, BPC-157 is one of six listed peptides that licensed pharmacies and physicians may compound under set conditions without federal enforcement action.1,4,5

Is BPC-157 FDA-approved?

Not FDA-approved

Not an FDA-approved drug2

Not FDA-approved. FDA staff recommended in May 2026 against adding TB-500 to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, TB-500 acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,4,5

Is TB-500 FDA-approved?

HHS compounding policy, October 30, 2026

In the policy: one of the six peptides it lists.5

In the policy: one of the six peptides it lists.5

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists BPC-157 among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.6

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists TB-500 among substances whose nominations were withdrawn and says FDA has not identified any human exposure data for it.6

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study One randomized, placebo-controlled study of a BPC-157 enema in 53 people with ulcerative colitis, reported only as a 2005 meeting abstract. FDA found its reported details inadequate to support efficacy or safety conclusions.1
  • Small, short, or incompletely reported human study Four other small human reports listed by FDA: enema studies in healthy volunteers, knee-pain injections in 17 people, bladder injections in 12 people with interstitial cystitis, and an intravenous safety pilot in two healthy adults.1
  • Registered trial without results A randomized Phase 2 trial in adults with an acute hamstring strain, first posted in February 2026 as recruiting, with no results posted.7
  • Registered trial without results A Phase 1 study in rotator cuff tears, listed as not yet recruiting in its September 3, 2026 registry record.8
  • Animal or laboratory research Most published research reports effects in rodent and laboratory models, including gut, liver, tendon and nerve injury models.1

Animal and lab studies only

  • Animal or laboratory research A laboratory study in which TB-500 did not speed the closing of scratch wounds in cultured cells, while one of its breakdown products had a small effect.2
  • Animal or laboratory research A study in aged mice in which a related fragment without TB-500’s acetyl group improved wound closure. FDA says those results cannot be directly carried over to TB-500.2
  • Animal or laboratory research Studies in horses and laboratory models showing that TB-500 reaches the bloodstream and is broken down into smaller fragments.2
  • Registered trial without results A Phase 1/2 trial of TB-500 in atherosclerotic cardiovascular disease and endothelial dysfunction, listed as recruiting in its March 23, 2026 registry record, with no results posted.9
Records collected

1 ClinicalTrials.gov record and 49 PubMed records collected

1 ClinicalTrials.gov record and 4 PubMed records collected

Area of study

Gut and digestion, Tissue repair and wound healing1,7

Tissue repair and wound healing2

Latest dated events
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists BPC-157 among six peptide substances used in compounding.4,5
  2. FDA’s Pharmacy Compounding Advisory Committee discusses BPC-157.10
  3. FDA staff date their evaluation recommending that BPC-157 not be added to the 503A bulks list.1
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists TB-500 among six peptide substances used in compounding.4,5
  2. FDA’s Pharmacy Compounding Advisory Committee discusses TB-500.10
  3. FDA staff date their evaluation recommending that TB-500 not be added to the 503A bulks list.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA briefing document for BPC-157-related bulk drug substances ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    FDA briefing document for TB-500 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    TB-500 substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked July 29, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  7. 7
    BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗

    ClinicalTrials.gov · Official source · Source checked July 22, 2026

  8. 8
    ClinicalTrials.gov record NCT07803250 · retained source version 2026-09-03:67a2d48128fcdff7f261f5c04e4a69cfe170396b0726d611a8db06ad7256abc0 ↗

    ClinicalTrials.gov · Official source · Source checked September 9, 2026

  9. 9
    ClinicalTrials.gov record NCT07487363 · retained source version 2026-03-23:eb4b60623fcf6b4ae3df79179184b1b2b5a5502180a2163da52ebf8c09c10e1e ↗

    ClinicalTrials.gov · Official source · Source checked August 14, 2026

  10. 10
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026